Scientific intelligence record
Experience 2.0
Alpha-MSH-derived tripeptide
Also known as: Lys-Pro-Val, α-MSH(11-13), KPV tripeptide
KPV is the C-terminal tripeptide Lys-Pro-Val of alpha-melanocyte-stimulating hormone. Preclinical studies associate KPV and related analogs with anti-inflammatory and antimicrobial effects, including modulation of NF-kB-linked signaling and epithelial inflammatory responses.
Record status
Traceability partial
Last meaningful update: 9/8/2026
Ranked research corpus
204
global evidence atlas
This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.
204 matching records · ranked 2026-09-18
Page 1 of 9
Europe PMC · 2026 · PMID 41880199 · DOI 10.23736/s0022-4707.26.17773-1
synthesis
Europe PMC · 2026 · PMID 41533788 · DOI 10.1126/sciadv.aea2989
preclinical-animal
Europe PMC · 2026 · PMID 42585803 · DOI 10.1016/j.tice.2026.103837
preclinical-animal
Europe PMC · 2026 · PMID 42064835 · DOI 10.1007/s10616-026-00967-z
preclinical-animal
Europe PMC · 2026 · PMID 40935835 · DOI 10.1038/s41418-025-01578-5
preclinical-animal
OpenAlex · 2025 · Source ID doi:10.1071/ch25144 · DOI 10.1071/ch25144
contextual-unclassified
Europe PMC · 2025 · PMID 41241376 · DOI 10.1016/j.drudis.2025.104535
preclinical-animal
Europe PMC · 2025 · PMID 40073467 · DOI 10.1016/j.tice.2025.102837
preclinical-animal
Europe PMC · 2025 · PMID 40030207 · DOI 10.1021/acsabm.4c01763
preclinical-animal
Europe PMC · 2024 · PMID 38289234 · DOI 10.1021/acsami.3c15684
preclinical-animal
Europe PMC · 2024 · PMID 39252648 · DOI 10.1002/adhm.202402320
preclinical-animal
Europe PMC · 2024 · PMID 38041747 · DOI 10.1007/s00467-023-06224-1
human-observational
Europe PMC · 2024 · PMID 39211778 · DOI 10.3389/fphar.2024.1442876
preclinical-animal
Europe PMC · 2023 · Source ID doi:10.1002/csc2.21096 · DOI 10.1002/csc2.21096
preclinical-animal
Europe PMC · 2023 · PMID 37860176 · DOI 10.1039/d3ra05248f
preclinical-animal
Europe PMC · 2023 · PMID 37161053 · DOI 10.1038/s41388-023-02703-9
preclinical-animal
WPF seed · 2022 · PMID 35245681 · DOI 10.1016/j.actbio.2022.02.039
preclinical-animal
Europe PMC · 2022 · PMID 35972627 · DOI 10.1007/s11274-022-03365-7
preclinical-animal
Europe PMC · 2022 · PMID 36240893 · DOI 10.1016/j.ijbiomac.2022.10.054
preclinical-animal
Europe PMC · 2021 · PMID 34846053 · DOI 10.1039/d1bm01466h
preclinical-animal
Europe PMC · 2021 · PMID 34662120 · DOI 10.1021/acsnano.1c05321
preclinical-animal
WPF seed · 2021 · PMID 34547895 · DOI 10.1021/acsbiomaterials.1c00792
preclinical-animal
Europe PMC · 2020 · PMID 33195893 · DOI 10.1021/acsomega.0c01462
human-interventional
Europe PMC · 2020 · PMID 32004526 · DOI 10.1016/j.ejphar.2020.172971
laboratory-mechanistic
Europe PMC · 2020 · Source ID doi:10.1101/2020.06.04.130963 · DOI 10.1101/2020.06.04.130963
preclinical-animal
governance and regulatory context
No new outcome conclusion is inferred from discovery metadata. Named accountable approval is required for governed scientific conclusions.
Absence of a record in this pass is not proof that no authorization exists. Status must remain jurisdiction-, product-, formulation-, and date-specific.
No centrally authorized EMA medicine for the named compound was identified in the EMA medicines database as of 8 September 2026.
European Medicines Agency medicines databaseNo FDA-approved drug product or therapeutic indication for the named compound was identified in Drugs@FDA as of 8 September 2026.
Drugs@FDA: FDA-Approved Drugs25 of 204 screening records carry a machine-proposed evidence-strength grade; the remainder are unassigned pending further review.
KPV evidence · ranking key
A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.
Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.
Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.
Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.
Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.
peptide explorer
Evidence-class labeling remains visible even when interactive rendering is unavailable. Representative geometry is not an experimentally determined or predicted biological conformation.
Fully specified molecular identity
Complete tripeptide identity; no coordinate-bearing structure is asserted.
Sources: NIH PubChem — Lys-Pro-Val / KPV · reviewed 2026-09-17
APA
World Peptide Foundation. (n.d.). KPV — Peptide Scientific Intelligence. World Peptide Foundation. (Reviewed September 8, 2026.) https://www.worldpeptidefoundation.org/directory/kpv
AMA / Vancouver
World Peptide Foundation. KPV — Peptide Scientific Intelligence. World Peptide Foundation website. Reviewed September 8, 2026. https://www.worldpeptidefoundation.org/directory/kpv
Categorized publications with transparent machine-proposed ranking; human appraisal pending.
Featured tiered studies
0
Cornerstone publications with study-level interpretation, limitations, and tier disclosure.
Research domains
6
Clinical and scientific questions synthesized independently across the evidence atlas.
Governed reviewed evidence
25
Database records promoted through the governed publication workflow—not the corpus total.
Corpus generated 2026-09-18. Counts remain separately labeled to prevent automated screening from being represented as completed human review.
Human experience · separate evidence stream
Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.
Observation is valuable human context. It is not evidence of causation, efficacy, or safety.
Public display gate
n ≥ 20 eligible observations
Exact progress remains private before the threshold.
Intelligence snapshot
A compact view of what is represented, what remains unresolved, and how completely the record can be traced.
Ranked research corpus
204
Categorized screening records; proposed rankings remain pending human appraisal.
Featured tiered studies
0
Cornerstone studies with published study-level interpretation and tier disclosure.
Research domains
6
Independent evidence dossiers covering the major research questions.
Governed reviewed evidence
25
Reviewed database records promoted through the governed publication workflow.
Contradictions
0
Conflicting evidence relationships that remain visible.
Research gaps
1
Questions the current record identifies as unresolved.
Connected media
0
Media records explicitly linked to this scientific record.
What we know
The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.
Reconciled domain conclusions
KPV no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded conclusion, confidence level, evidence synthesis, limitations, geographic applicability, regulatory interpretation, and research gaps.
Inspect the reconciled evidence atlasThis score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Scientific context
Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.
Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.
Explore further
Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.
Research
Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.
1979 · study · Temporal status not established
peer_reviewed_research
1982 · study · Temporal status not established
peer_reviewed_research
1982 · study · Temporal status not established
peer_reviewed_research
1984 · study · Temporal status not established
peer_reviewed_research
1989 · study · Temporal status not established
peer_reviewed_research
1992 · study · Temporal status not established
peer_reviewed_research
1994 · study · Temporal status not established
peer_reviewed_research
1994 · study · Temporal status not established
peer_reviewed_research
1996 · study · Temporal status not established
peer_reviewed_research
1996 · study · Temporal status not established
peer_reviewed_research
1998 · study · Temporal status not established
peer_reviewed_research
2001 · study · Temporal status not established
peer_reviewed_research
2001 · study · Temporal status not established
peer_reviewed_research
2001 · study · Temporal status not established
peer_reviewed_research
2002 · study · Temporal status not established
peer_reviewed_research
2003 · study · Temporal status not established
peer_reviewed_research
2005 · study · Temporal status not established
peer_reviewed_research
2007 · study · Temporal status not established
peer_reviewed_research
2008 · study · Temporal status not established
peer_reviewed_research
2010 · study · Temporal status not established
peer_reviewed_research
2013 · study · Temporal status not established
peer_reviewed_research
2017 · study · Temporal status not established
peer_reviewed_research
2019 · study · Temporal status not established
peer_reviewed_research
2021 · study · Temporal status not established
peer_reviewed_research
2022 · study · Temporal status not established
peer_reviewed_research
2026 · regulatory · Temporal status not established
European Union (EMA)
2026 · regulatory · Temporal status not established
United States (FDA)
The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.
No institutional claim record is currently represented for this peptide.
Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.
These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.
6 represented evidence records
Years represented: 1982, 1984, 1989, 1996, 2013
Publishing organizations appearing in records: peer_reviewed_research
5 represented evidence records
Years represented: 1994, 2003, 2005, 2007
Publishing organizations appearing in records: peer_reviewed_research
4 represented evidence records
Years represented: 1982, 1984, 1989, 1996
Publishing organizations appearing in records: peer_reviewed_research
3 represented evidence records
Years represented: 1984, 1989, 1996
Publishing organizations appearing in records: peer_reviewed_research
3 represented evidence records
Years represented: 2003, 2005, 2007
Publishing organizations appearing in records: peer_reviewed_research
Connections
Connections appear only when they are represented by the project’s underlying records.
institution
Traceability
The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.
Source publication state
A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.
Reviewer provenance state
“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.
Domain conclusion → Evidence
Connected
Evidence → Source
Connected
Source → Original record
Connected
Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.
Reconciled for 6 domain conclusions and 0 featured studies.
Detailed study-to-domain mappings and original-source paths appear in the KPV evidence-governance section.
Inspect the ranked source recordsObservational archive
Observational archive data is intentionally separated from published scientific evidence.
Observational boundary
Insufficient eligible observations are available for display under the current filters.
Insufficient eligible observations are currently represented to display aggregated findings for this peptide.
Regulatory context
Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.
European Union (EMA)
Regulator: EMA
As of: 9/8/2026 · Temporal status not established
United States (FDA)
Regulator: FDA
As of: 9/8/2026 · Temporal status not established
Research + media
Only media explicitly linked through the project’s relationship system appears here.
No scientifically connected media is currently represented for this peptide.
Sources + provenance
Generated: 9/24/2026, 3:24:30 AM
Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.
Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.
This is a representative, sequence-derived model ordered by residue position only. It is not the peptide's experimentally determined or predicted biological conformation, and it carries no claim about real bond angles, distances, secondary structure, binding sites, or activity.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
KPV (Lys-Pro-Val), which is a tripeptide derived from alpha-MSH (alpha-melanocyte-stimulating hormone), has an anti-inflammatory effect on colitis. ...
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
MMPB was found to cross-react with an antiserum specific for the Lys-Pro-Val NH2 sequence in alpha-MSH, indicating that this C-terminal sequence of alpha-MSH may be present in its structure. ...
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The injections of anti-rat tumor necrosis factor-alpha, interleukin-1beta polyclonal neutralizing antibody, alpha-melanocyte-stimulating hormone, and KPV peptide (Ac-D-Lys-L-Pro-D-Val) might prevent a reduction in the binding capacity of glucocorticoid receptor in h …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Changes in Rt and Kd of aldosterone binding activity were observed after injection of anti-rat TNF alpha and IL-1 beta antibodies, alpha-melanocyte-stimulating hormone (alpha-MSH) and KPV peptide (Ac-D-Lys-L-Pro-D-Val). The results indicated that there were two type …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
We engineered nanoparticles (NPs) to deliver an anti-inflammatory tripeptide Lys-Pro-Val (KPV) to the colon and assessed its therapeutic efficacy in a mouse model of colitis. ...CONCLUSIONS: Nanoparticles are a versatile drug delivery system that can overcome …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The potent and enzymatically stable analogue NDP-MSH (Ac-Ser-Tyr-Ser-Nle-Glu-His-DPhe-Arg-Trp-Gly-Lys-Pro-Val-NH(2)) is a lead peptide for the identification of melanocortin amino acids important for receptor molecular recognition and stimulation. ...
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
In vivo imaging confirmed that PMSP specifically adhered to the inflamed colonic mucosa of rats with TNBS-induced UC. KPV (Lys-Pro-Val) as a model drug was easily captured by PMSP through electrostatic interactions, thus retaining its bioactivity for a longer …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
alpha-Melanocyte-stimulating hormone (alpha-MSH1-13) and its COOH-terminal tripeptide alpha-MSH11-13 (Lys Pro Val) inhibit inflammation when administered systemically. Recent evidence indicates that alpha-MSH1-13 can likewise inhibit inflammation in the skin …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
This peer-reviewed source examines Cyclic melanotropins. 5. Importance of the C-terminal tripeptide (Lys-Pro-Val).
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Ac-Ser.Tyr-Ser-Nle4-Glu- His-DPhe7-Arg-Trp-Gly-Lys-Pro-Val-NH2(NDP-MSH), led to the discovery of tripeptide agonists possessing prolonged bioactivity in the frog skin assay. ...
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
This peer-reviewed source examines Synthesis and characterization of time-resolved fluorescence probes for evaluation of competitive binding to melanocortin receptors.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
We recently demonstrated that alpha-MSH and its C-terminal sequence Lys-Pro-Val (alpha-MSH (11-13)) have antimicrobial effects against two major and representative pathogens: Staphylococcus aureus and Candida albicans. ...Because previous data suggested that …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
BACKGROUND & AIMS: KPV is a tripeptide (Lys-Pro-Val), which possesses anti-inflammatory properties; however, its mechanisms of action still remain unknown. ...
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Variation in the degree of prolonged (residual) biological activity of the melanotropin peptides alpha-MSH (alpha-melanocyte-stimulating hormone, Ac-Ser-Tyr-Met-Glu- His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) and the superpotent analogues [Nle4,DPhe7]alpha-MSH (MT- …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
As a good receptor, the oligopeptide transporter (PepT1) is overexpressed in the colonic epithelial cells of chronic ulcerative colitis, which can deliver tripeptide KPV (Lys-Pro-Val, the C-terminal sequence of alpha-MSH) into cytosol in the intestine. Herein …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
In the last year, it has been shown that the majority of cutaneous cell types express the melanocortin 1 receptor (MC1R) that binds alpha-melanocyte-stimulating hormone (alpha-MSH) with high affinity and elicits pleiotropic biological effects, for example modulation of inflammati …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Previous research has shown that the immunomodulatory peptide alpha-melanocyte-stimulating hormone (alpha-MSH) and its carboxy-terminal tripeptide KPV (Lys-Pro-Val alpha-MSH11-13) have antimicrobial influences. By inserting a Cys-Cys linker between two units …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
We firstly demonstrated that alpha-MSH and its C-terminal sequence Lys-Pro-Val [alpha-MSH(11-13)] have antimicrobial effects against two major and representative pathogens: Staphylococcus aureus and Candida albicans. ...We focused on the sequence alpha-MSH(6- …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Antipyretic and anti-inflammatory activities of alpha-MSH are due to the COOH-terminal peptide sequence, Lys-Pro-Val (alpha-MSH[11-13]). This tripeptide might be useful as a therapeutic agent in the control of fever and inflammatory reactions. ...
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
An N-terminal amino acid sequence analysis from the amino-terminal residue gave, for the first 32 residues, Asp-Ile-Leu-Ile-Ala-Gly-Ala-Thr-Gly-Asn-Val-Gly-Lys-Pro-Leu-Val-Glu-Gly-Leu-Leu - Ala-Ala-Gly-Lys-Pro-Val-Arg-Ala-Leu-Thr-Arg-Asn... The sequence from …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Hyperalgesic responses to IL-1 beta were inhibited in a dose-dependent manner by alpha-melanocyte stimulating hormone (alpha-MSH)-related peptides with the following order of potency: [N1(4),D-Phe7]alpha-MSH greater than alpha-MSH greater than Lys-D-Pro-Val greater than Lys …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
alpha-Melanocyte-stimulating hormone (alpha-melanotropin; alpha-MSH) is a linear tridecapeptide (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) that reversibly darkens amphibian skins by stimulating melanomsome (pigment granule) dispersion within …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
This peptide and a tripeptide that forms the COOH-terminal portion of the molecule (alpha-MSH11-13; Lys Pro Val) inhibit inflammation when given centrally or peripherally. Because of the similarity in their actions, the tripeptide has been presumed to be the …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The solution structures of both melanocyte-stimulating hormone alpha-MSH (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) and its analog alpha-MSH-ND (Ac-Ahx-Asp-His-DPhe-Arg-Trp-Lys-NH2) (Ahx, 2-aminohexanoic acid) have been determined by two-dim …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
alpha-Melanocyte stimulating hormone (alpha-MSH) is a linear tridecapeptide (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) that has diverse physiological functions in addition to its reversible darkening of amphibian skins by stimulating melanos …
3 represented evidence records
Years represented: 1982, 1984, 1989
Publishing organizations appearing in records: peer_reviewed_research
4 represented evidence records
Years represented: 1994, 2003, 2005
Publishing organizations appearing in records: peer_reviewed_research
3 represented evidence records
Years represented: 2003, 2005, 2007
Publishing organizations appearing in records: peer_reviewed_research
2 represented evidence records
Years represented: 2001, 2002
Publishing organizations appearing in records: peer_reviewed_research
2 represented evidence records
Years represented: 2003, 2005
Publishing organizations appearing in records: peer_reviewed_research
2 represented evidence records
Years represented: 2008, 2010
Publishing organizations appearing in records: peer_reviewed_research
2 represented evidence records
Years represented: 2001, 2002
Publishing organizations appearing in records: peer_reviewed_research